Akebia Therapeutics, Inc. (AKBA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Assertio Holdings, Inc.

IGM Biosciences, Inc.

Akebia Therapeutics, Inc.

scPharmaceuticals, Inc.

Y-mAbs Therapeutics, Inc.

Enanta Pharmaceuticals, Inc.

Ocular Therapeutix, Inc.

Vanda Pharmaceuticals, Inc.

AC Immune SA

Lifecore Biomedical, Inc.

AEON Biopharma, Inc.

Why is Akebia Therapeutics, Inc. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -6.09% and Operating profit at 15.61% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.82

With a growth in Net Sales of 2.41%, the company declared Outstanding results in Sep 25

OPERATING CASH FLOW(Y) Highest at USD 32.38 MM
NET SALES(HY) At USD 121.24 MM has Grown at 49.54%
PRE-TAX PROFIT(Q) At USD -0.31 MM has Grown at 95.44%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -34.27%, its profits have risen by 82.7%

High Institutional Holdings at 52.42%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 6.05% over the previous quarter.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 16.12% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -34.27% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Akebia Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Akebia Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Akebia Therapeutics, Inc.

-34.27%

0.40

71.83%

S&P 500

16.12%

0.84

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-6.09%

EBIT Growth (5y)

15.61%

EBIT to Interest (avg)

-8.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

3.69

Sales to Capital Employed (avg)

1.92

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

52.42%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

9.73

EV to EBIT

25.34

EV to EBITDA

13.95

EV to Capital Employed

5.18

EV to Sales

2.00

PEG Ratio

Dividend Yield

ROCE (Latest)

20.46%

ROE (Latest)

-19.45%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 32.38 MM

NET SALES(HY)

At USD 121.24 MM has Grown at 49.54%

PRE-TAX PROFIT(Q)

At USD -0.31 MM has Grown at 95.44%

NET PROFIT(Q)

At USD -0.14 MM has Grown at 97.87%

RAW MATERIAL COST(Y)

Fallen by -37.05% (YoY

-5What is not working for the Company

INTEREST(HY)

At USD 11.58 MM has Grown at 31.46%

Here's what is working for Akebia Therapeutics, Inc.

Operating Cash Flow

Highest at USD 32.38 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit

At USD -0.31 MM has Grown at 95.44%

over average net sales of the previous four periods of USD -6.78 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -0.14 MM has Grown at 97.87%

over average net sales of the previous four periods of USD -6.78 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

At USD 121.24 MM has Grown at 49.54%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Raw Material Cost

Fallen by -37.05% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Akebia Therapeutics, Inc.

Interest

At USD 11.58 MM has Grown at 31.46%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)